Results 1 to 10 of about 2,382,231 (215)

Mu Opioid Receptor Heterodimers Emerge as Novel Therapeutic Targets: Recent Progress and Future Perspective

Frontiers in Pharmacology, 2020
Opioids are the most effective analgesics used in the clinical management of cancer pain or non-cancer pain. However, chronic opioids therapy can cause many side effects including respiratory depression, nausea, sedation, itch, constipation, analgesic ...
Li Zhang, Jiang-Tao Zhang, Lihua Hang, Tong Liu, Tong Liu   +4 more
doaj   +2 more sources

Toll-Like Receptor 4 (TLR4)/Opioid Receptor Pathway Crosstalk and Impact on Opioid Analgesia, Immune Function, and Gastrointestinal Motility

Frontiers in Immunology, 2020
Toll-like receptor 4 (TLR4) recognizes exogenous pathogen-associated molecular patterns (PAMPs) and endogenous danger-associated molecular patterns (DAMPs) and initiates the innate immune response.
Peng Zhang, Meirong Yang, Chunhua Chen, Liu Liu, Xinchuan Wei, Si Zeng   +5 more
doaj   +2 more sources

Ligand and G-protein selectivity in the κ-opioid receptor

Nature, 2023
The κ-opioid receptor (KOR) represents a highly desirable therapeutic target for treating not only pain but also addiction and affective disorders^ 1 .
Jianming Han, Jingying Zhang, Antonina L. Nazarova, Sarah M. Bernhard, Brian E. Krumm, Lei Zhao, J. Lam, V. Rangari, S. Majumdar, David E. Nichols, V. Katritch, Peng Yuan, Jonathan F. Fay, Tao Che   +13 more
semanticscholar   +1 more source

Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain

Frontiers in Molecular Neuroscience, 2022
Opioids mediate their effects via opioid receptors: mu, delta, and kappa. At the neuronal level, opioid receptors are generally inhibitory, presynaptically reducing neurotransmitter release and postsynaptically hyperpolarizing neurons.
Kaitlin C. Reeves, Nikhil P. Shah, B. Muñoz, Brady K. Atwood   +3 more
semanticscholar   +1 more source

Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors

Pharmaceuticals, 2022
The delta opioid receptor is a Gi-protein-coupled receptor (GPCR) with a broad expression pattern both in the central nervous system and the body. The receptor has been investigated as a potential target for a multitude of significant diseases including ...
Yazan J. Meqbil, Richard M. van Rijn
doaj   +1 more source

Prescription analgesic overuse in older adults: Can we mitigate this growing problem?

AGING MEDICINE, Volume 5, Issue 4, Page 294-296, December 2022., 2022
With older adults already on numerous prescription medications to manage their chronic conditions, the addition of pain medications could impose an even greater burden due to dependency issues. We need to understand the use of chronic pain medication, especially opioids, discuss current strategies and gaps, and offer potential solutions to mitigate ...
Sara Kakatkar, Aditya Narayan, Rajesh Balkrishnan   +2 more
wiley   +1 more source

A prospective randomized controlled study on the role of restoring liver diaphragm surface tension and pain control at port sites in optimizing pain management following laparoscopic cholecystectomy

Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 131-137, January 2023., 2023
The cornerstone of treatment for symptomatic gallbladder stones is laparoscopic cholecystectomy. Pain is the commonest cause of extended hospital stay. Disturbance of liver—diaphragm surface tension is the main cause of pain. Retained CO2 is a major concern post laparoscopic cholecystectomy.
Mohamed Lotfy Ali Abuelzein, Mohamed Ali Baghdadi, Waleed Ahmed Abbdelhady, Mostafa Mohamed Khairy   +3 more
wiley   +1 more source

Nanobody-enabled monitoring of kappa opioid receptor states

Nature Communications, 2020
Recent studies show that GPCRs rapidly interconvert between multiple states although our ability to interrogate, monitor and visualize them is limited by a relative lack of suitable tools.
T. Che, J. G. English, B. Krumm, Kuglae Kim, E. Pardon, Reid H. J. Olsen, Sheng Wang, Sheng Wang, Shicheng Zhang, J. Diberto, N. Sciaky, F. Carroll, J. Steyaert, Daniel Wacker, Daniel Wacker, B. Roth   +15 more
semanticscholar   +1 more source

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

American Journal of Hematology, Volume 98, Issue 1, Page 11-22, January 2023., 2023
Treatment process evolution. *The target TNC for BMH was ≥6 × 108/kg per patient. The Group B1 patient received lovo‐cel produced using both the original and refined manufacturing process, and the Group B2 patient received lovo‐cel produced using only the refined manufacturing process.
Julie Kanter, Alexis A. Thompson, Francis J. Pierciey Jr, Matthew Hsieh, Naoya Uchida, Philippe Leboulch, Manfred Schmidt, Melissa Bonner, Ruiting Guo, Alex Miller, Jean‐Antoine Ribeil, David Davidson, Mohammed Asmal, Mark C. Walters, John F. Tisdale   +14 more
wiley   +1 more source

A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain

Pain and Therapy, 2020
Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid receptor agonists.
Jeffrey Gudin, Jeffrey Fudin
doaj   +1 more source